Calreticulin mutant mice develop essential thrombocythemia that is ameliorated by the JAK inhibitor ruxolitinib.

Shide K, Kameda T, Yamaji T, Sekine M, Inada N, Kamiunten A, Akizuki K, Nakamura K, Hidaka T, Kubuki Y, Shimoda H, Kitanaka A, Honda A, Sawaguchi A, Abe H, Miike T, Iwakiri H, Tahara Y, Sueta M, Hasuike S, Yamamoto S, Nagata K, Shimoda K
Leukemia. 2016 Nov 29. doi: 10.1038/leu.2016.308. PubMed Article

Plasmids from Article

No plasmids are currently publicly available from Addgene for this article.